A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

NCT03960502 | Completed Phase 1 FDA Drug

• 1 other identifier: AG881-C-005
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this Phase I, open-label study is to evaluate the absorption, distribution, metabolism, excretion, absolute bioavailability, and to characterize the metabolites of AG-881 in healthy male participants following administration of a single oral dose of \[14C\] AG-881 and a concomitant intravenous microdose of \[13C315N3\] AG-881.

Conditions

Healthy Male Participants

Keywords

Safety and tolerability; Pharmacokinetic study

Outcome Measures

Primary Outcomes (24)

• Amount of AG-881 Excreted in Urine (Aeu)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Cumulative Aeu (Cum Aeu) of AG-881

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Percentage of AG-881 excreted in Urine and Feces (feu and fef, Respectively)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Cumulative Percentage of AG-881 Excreted in Urine (Cum feu)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Cumulative Percentage of AG-881 Excreted in Feces (Cum fef)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Renal Clearance (CLR) of AG-881

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Renal Clearance Expressed as a Percentage of Total Clearance (CLR/CL) of AG-881

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Percentage of Total Radioactivity in Total Excreta Calculated as Cumulative Percentage of AG-881 Excreted in Urine and Feces (Cum fe)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of AG-881

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Area Under the Concentration-time Curve from Time Zero to 72 hours (AUC0-72) of AG-881

  Up to 72 hours

• Partial Area Under the Concentration-time Curve from Time Zero to Common Time Point (AUC0-t) of AG-881

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Area Under the Concentration-time Curve from Time Zero to Infinity (AUC0-∞) of AG-881 Calculated Using the Observed Value of the Last Quantifiable Concentration

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Maximum Observed Plasma Concentration (Cmax) of AG-881

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Time to Maximum Observed Plasma Concentration (Tmax) of AG-881

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Apparent Terminal Elimination Half-life (t½) of AG-881

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• AUC0-∞ or AUC0-t of AG-881 in Plasma/AUC0-∞ or AUC0-t of Total Radioactivity in Plasma (AUC Plasma AG-881/Total Radioactivity Ratio)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• AUC0-∞ of Total Radioactivity in Whole Blood to AUC0-∞ of Total Radioactivity in Plasma (AUC Blood/Plasma Ratio), Calculated Using the Observed Value of the Last Quantifiable Concentration

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Total Clearance of AG-881 Following Intravenous (IV) Administration (CL)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Apparent Clearance Following Oral Administration of AG-881 (CL/F)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Volume of Distribution of AG-881 at Steady-state Following IV Administration (Vss)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Apparent Volume of Distribution During the Terminal Phase Following Oral Administration of AG-881 (Vz/F)

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Absolute bioavailability (F) for AG-881 Calculated as the Ratio of Dose-normalized AUC0-∞ of Oral/Intravenous Dosing

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Metabolic Profiles of AG-881 in Plasma, Urine, and Feces, When Possible

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

• Structures of AG-881 Metabolites in Plasma, Urine, and, Where Possible, Feces

  At multiple time points daily from Day -1 to Day 14; then at 24-hour intervals until discharge (up to 29 days); then weekly up to approximately 8 weeks

Secondary Outcomes (5)

• Percentage of Participants with Adverse Events (AEs), Graded by Severity

  Up to approximately 12 weeks

• Percentage of Participants with Laboratory Abnormalities

  Up to approximately 8 weeks

• Percentage of Participants with Abnormalities in 12-lead Electrocardiogram (ECG)

  Up to approximately 8 weeks

• Percentage of Participants with Abnormalities in Vital Signs Measurements

  Up to approximately 8 weeks

• Percentage of Participants with Abnormalities in Physical Examinations

  Up to approximately 8 weeks

Study Arms (1)

AG881

EXPERIMENTAL

On Day 1, after fasting for 10 hours participants, will receive an oral capsule of \[14C\]AG-881 followed 2 hours later by a single intravenous (IV) infusion of \[13C315N3\]AG-881.

Drug: AG-881; Drug: [13C315N3]AG-881

Interventions

AG-881 DRUG

Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of \[14C\]AG-881.

AG881

[13C315N3]AG-881 DRUG

Single IV microdose of approximately 100 μg.

AG881

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions, including confinement, as well as adhere to all study procedures;
• Males of any race, between 18 and 55 years of age, inclusive;
• Body mass index between 18.0 and 32.0 kilograms per meter squared (kg/m\^2), inclusive, and a total body weight between 50 and 100 kg, inclusive;
• In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, and clinical laboratory evaluations (congenital non-hemolytic hyperbilirubinemia \[e.g., suspicion of Gilbert's syndrome based on total and direct bilirubin\] is not acceptable) at Screening and/or Check-in (Day -1), as assessed by the Investigator (or designee);
• Alanine aminotransferase (ALT; at or within normal limits \[WNL\]), aspartate aminotransferase (AST; at or within normal limits), alkaline phosphatase (ALP; \<1.5 × upper limit of normal \[ULN\]), bilirubin (at or below WNL). One repeat assessment allowed at each time point;
• Male participants will agree to use contraception;
• Agrees to abstain from any alcohol consumption, starting 48 hours before Check-in (Day -1) and continuing until Discharge;
• History of a minimum of one bowel movement per day;
• Adequate peripheral venous access.

You may not qualify if:

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee);
• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee);
• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed);
• Has undergone any major surgical procedure within the 3 months prior to Screening;
• History of alcoholism or drug/chemical abuse within 2 years prior to Check-in (Day -1);
• History of severe and/or uncontrolled ventricular arrhythmias or other factors that increase the risk of long QT syndrome, or use, or intend to use, medications that are known to prolong the QT interval or history of unexplained syncopal events or familial history of unexplained death in young person;
• After at least 5 minutes of rest in the supine position at Screening, has a systolic blood pressure reading of ≥140 millimeters of mercury (mmHg) OR a diastolic blood pressure reading of ≥90 mmHg;
• A heart rate-corrected QT interval by Fridericia's (QTcF) method of ≥450 milliseconds (ms);
• Alcohol consumption of \>21 units per week. One unit of alcohol equals 12 ounces (360 millimeters \[mL\]) of beer, 1½ oz (45 mL) of liquor, or 5 oz (150 mL) of wine;
• Positive urine drug screen at Screening or positive alcohol breath test result or positive urine drug screen at Check-in (Day -1);
• Positive hepatitis panel and/or positive human immunodeficiency virus test;
• Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days or 5 half-lives (whichever is longer), prior to dosing;
• Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in (Day -1), unless deemed acceptable by the Investigator (or designee);
• Use or intend to use any prescription medications/products within 14 days prior to Check-in (Day -1), unless deemed acceptable by the Investigator (or designee);
• Use or intend to use slow-release medications/products considered to still be active within 30 days prior to Check-in (Day -1), unless deemed acceptable by the Investigator (or designee);

Sponsors & Collaborators

• Agios Pharmaceuticals, Inc.: lead

Study Sites (1)

Covance Clinical Research Unit Inc.

Madison, Wisconsin, 53704, United States

Location

Study Officials

• Medical Affairs

  Agios Pharmaceuticals, Inc.

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 21, 2019
• First Posted: May 23, 2019
• Study Start: May 16, 2019
• Primary Completion: September 7, 2019
• Study Completion: September 7, 2019
• Last Updated: October 23, 2019

Record last verified: 2019-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)